MARKET

ABSI

ABSI

Absci Corp
NASDAQ
3.260
-0.040
-1.21%
After Hours: 3.310 +0.05 +1.53% 16:25 01/27 EST
OPEN
3.260
PREV CLOSE
3.300
HIGH
3.440
LOW
3.230
VOLUME
515.11K
TURNOVER
0
52 WEEK HIGH
9.68
52 WEEK LOW
1.940
MARKET CAP
301.21M
P/E (TTM)
-2.6695
1D
5D
1M
3M
1Y
5Y
MNPR and NXL among healthcare movers
Seeking Alpha · 5d ago
BLCM, NVVE and BYSI among mid-day movers
Seeking Alpha · 01/19 18:12
Absci to Participate in the Berenberg Discover AI Seminar
VANCOUVER, Wash. and NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Berenberg Discover AI Seminar in New York, NY. Absci...
GlobeNewswire · 11/23/2022 13:00
BRIEF-Absci Corp Third Quarter Revenue $2.4 Million
Reuters · 11/09/2022 15:50
Absci reports $27M loss but strong holdings
The company continued to lose money but its CEO says it has enough cash to sustain it through the end of 2025.
American City Business Journals · 11/09/2022 15:47
Absci Corporation (ABSI) Reports Q3 Loss, Tops Revenue Estimates
Absci Corporation (ABSI) delivered earnings and revenue surprises of -11.11% and 32.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09/2022 14:15
Absci GAAP EPS of -$0.30 misses by $0.02, revenue of $2.37M beats by $0.5M
Seekingalpha · 11/09/2022 13:46
Absci Q3 EPS $(0.30) Up From $(0.33) YoY, Sales $2.37M Up From $1.54M YoY
Benzinga · 11/09/2022 13:15
More
About ABSI
Absci Corporation is a drug and target discovery company. The Company has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. It uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The Company has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. It has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.

Webull offers kinds of Absci Corp stock information, including NASDAQ:ABSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABSI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABSI stock methods without spending real money on the virtual paper trading platform.